✉ Email this page to a colleague
« Back to Dashboard
Glecaprevir; pibrentasviris the generic ingredient in one branded drug marketed by Abbvie Inc and is included in two NDAs. There are nine patents protecting this compound. Additional information is available in the individual branded drug profile pages.
Glecaprevir; pibrentasvir has five hundred and fourteen patent family members in forty-five countries.
One supplier is listed for this compound.
Recent Clinical Trials for glecaprevir; pibrentasvir
Identify potential brand extensions & 505(b)(2) entrants
|NYU Langone Health||Early Phase 1|
|Mayo Clinic||Phase 4|
Pharmacology for glecaprevir; pibrentasvir
|Company||Drugname||Inn||Product Number / Indication||Status||Generic||Biosimilar||Orphan||Marketing Authorisation||Marketing Refusal|
|AbbVie Deutschland GmbH Co. KG||Maviret||glecaprevir, pibrentasvir||EMEA/H/C/004430
Maviret is indicated for the treatment of chronic hepatitis C virus (HCV) infection in adults and children aged 3 years and older.Maviret coated granules is indicated for the treatment of chronic hepatitis C virus (HCV) infection in children 3 years and older.
|>Company||>Drugname||>Inn||>Product Number / Indication||>Status||>Generic||>Biosimilar||>Orphan||>Marketing Authorisation||>Marketing Refusal|
|Country||Patent Number||Title||Estimated Expiration|
|Australia||2018201011||Methods for treating HCV||See Plans and Pricing|
|Dominican Republic||P2019000218||See Plans and Pricing|
|Australia||2020239679||Crystal forms||See Plans and Pricing|
|Ecuador||SP11010937||COMPUESTOS ANTIVIRALES||See Plans and Pricing|
|Mexico||2018002707||DERIVADOS DE TETRAHIDROFURANO ANTIVIRALES. (ANTI-VIRAL TETRAHYDROFURANE DERIVATIVES.)||See Plans and Pricing|
|Mexico||343275||See Plans and Pricing|
|>Country||>Patent Number||>Title||>Estimated Expiration|
|Patent Number||Supplementary Protection Certificate||SPC Country||SPC Expiration||SPC Description|
|2368890||639||Finland||See Plans and Pricing|
|2692346||300901||Netherlands||See Plans and Pricing||PRODUCT NAME: PIBRENTASVIR OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN; REGISTRATION NO/DATE: EU/1/17/1213 20170728|
|2618831||2017056||Norway||See Plans and Pricing||PRODUCT NAME: GLEKAPREVIR ELLER ET; REG. NO/DATE: EU/1/17/1213 20170807|
|2692346||CR 2017 00049||Denmark||See Plans and Pricing||PRODUCT NAME: PIBRENTASVIR OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; REG. NO/DATE: EU/1/17/1213 20170728|
|2692346||1790050-7||Sweden||See Plans and Pricing||PRODUCT NAME: PIBRENTASVIR OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; REG. NO/DATE: EU/1/17/1213 20170728|
|2618831||PA2017034,C2618831||Lithuania||See Plans and Pricing||PRODUCT NAME: GLEKAPREVIRAS ARBA JO FARMACINIU POZIURIU PRIIMTINA DRUSKA ARBA ESTERIS; REGISTRATION NO/DATE: EU/1/17/1213 20170726|
|>Patent Number||>Supplementary Protection Certificate||>SPC Country||>SPC Expiration||>SPC Description|
Make Better Decisions: Try a trial or see plans & pricing
Serving leading biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.